N/A N=27 Randomized Double-blind Basic Science

Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?

Migraine

Bottom Line

View on ClinicalTrials.gov: NCT00360282 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Dec 2014

Primary outcome: Primary: Change From Baseline in Motion Sickness to Post Vestibular Stimulus — 5.1; 9 units on a scale — p=0.007

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Rizatriptan (Drug); Placebo (Other)
Age: Adult · 21+ yrs
Sex: All
Sponsor: University of Pittsburgh
Primary completion: Jan 2009

Outcome Measures

Outcome	Result	p-value
PRIMARY Change From Baseline in Motion Sickness to Post Vestibular Stimulus	5.1; 9	0.007 sig
SECONDARY Change From Baseline in Subjective Units of Distress to Post Vestibular Stimulus	3; 2	.549

Summary

The purpose of this study is to determine if Rizatriptan, a migraine medication, lowers motion sickness in migraine sufferers.

Eligibility Criteria

Inclusion Criteria

History of motion sickness
Currently suffering from migraines with at least 2 episodes during the previous 12 months
Previous use and tolerance to triptans

Exclusion Criteria

Current tobacco user
History of or current hypertension, cardiac disease, arrhythmia, hypercholesterolemia, hemiplegic/basilar migraine, stroke, diabetes, vascular disease or kidney disease
Family history of early myocardial infarction (first-degree relative 20/40 O.U.
Women who are pregnant or breastfeeding

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00360282). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.